XCancer

68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors

Description:

This study aims to evaluate a novel dual-targeted PET imaging tracer, 68Ga-FAPI-PSMA, for the detection and evaluation of solid tumors. Fibroblast activation protein (FAP) and prostate-specific membrane antigen (PSMA) are two important molecular targets that are highly expressed in tumor cells or the tumor microenvironment. Combining these two targets into a single imaging probe may improve the sensitivity and accuracy of tumor detection. In this single-center, open-label, self-controlled study, approximately 20 patients with suspected or confirmed solid tumors will undergo PET/CT imaging using 68Ga-FAPI-PSMA. The imaging results will be compared with standard PET tracers such as 68Ga-PSMA-617 or 68Ga-FAPI-04. The study will assess tracer uptake in tumor lesions and compare diagnostic performance between imaging methods. The results may help determine whether 68Ga-FAPI-PSMA PET/CT can improve tumor detection, staging, and clinical evaluation in patients with solid tumors.

Sponsor:

Peking University Cancer Hospital & Institute

Phase:

N/A

Contacts:

yifei pei (CONTACT)

peiyfiei0523@163.com

+86 15602222734

Government Study Link:

NCT07639801 - Click here to see study on

ClinicalTrials.gov

FAPI-04

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA

FAPI-PSMA

Isotope(s):
Target(s):
  • αvβ6/FAP
Ligand Class: Small Molecules

PSMA-617

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: DOTA
Inclusion
  • * Age 18-75 years
  • Patients scheduled to undergo tumor biopsy or surgical treatment within 2 months
  • ECOG performance status of 0 or 1
  • Patients with suspected or confirmed solid tumors (e.g., prostate cancer, hepatocellular carcinoma, ovarian cancer, or endometrial cancer)
  • Expected survival of at least 12 weeks
Exclusion
  • Refusal or inability to participate in the clinical study
  • Inability to remain in a supine position for approximately 30 minutes during PET/CT scanning
  • * Severe hepatic or renal dysfunction
  • Claustrophobia or severe psychiatric disorders that would interfere with imaging procedures
  • Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study